

Table S1. Chemical substances and concentrations used as positive controls for Ames test.

Strain	Without S9 mix		With S9 mix	
	Chemical substance	Dose ($\mu\text{g}/\text{plate}$)	Chemical substance	Dose ($\mu\text{g}/\text{plate}$)
TA98	2-Nitrofluorene	1	2-Aminoanthracene	1
TA100	Sodium azide	1	Benzo(a)pyrene	1
Ta102	Mitocin C	0.2	2-Aminoanthracene	5
TA1535	Sodium azide	1	2-Aminoanthracene	5
TA1537	9-Aminoacridine	50	2-Aminoanthracene	5

Table S2. Genotype of *S. typhimurium* strains.

Strains	Histidine mutation	LPS	Repair(Δ <i>uvrB</i> ¹)	R-factor	pAQ1 plasmid
TA97a	<i>hisD6610</i>	<i>rfa</i>	Δ <i>uvrB</i>	+R	-
	<i>his01242</i>	<i>rfa</i>	Δ <i>uvrB</i>		
TA98	<i>hisD3052</i>	<i>rfa</i>	Δ <i>uvrB</i>	+R	-
TA100	<i>hisG46</i>	<i>rfa</i>	Δ <i>uvrB</i>	+R	-
TA102	<i>hisG428</i>	<i>rfa</i>	+ ²	+R	+ ³
TA1535	<i>hisG46</i>	<i>rfa</i>	Δ <i>uvrB</i>	-R	-

1: " Δ " mean gene deletion.

2: "+²" means wild-type gene.

3: Insertion of the mutation *hisG428* on the multicopy plasmid pAQ1.

Table S3. Results of dose range finding test of LACC in TA98 strain.

Dose (mg/plate)	Number of revertants/plate (mean \pm S.D., n = 3)
TA98	Without S9 mixture
Negative control (sterile water)	19.0 \pm 3.6
Positive control	120.7 \pm 14.0*
LACC (mg/plate)	
5	24.3 \pm 5.5
2.5	18.3 \pm 3.1
1.25	27.0 \pm 0.0
0.625	27.0 \pm 2.0
0.313	25.0 \pm 1.0

*indicates statistically significant ($p < 0.05$) from negative control group.

Concentration of positive control in *Salmonella typhimurium* TA98.

TA98	Positive control	Concentration ($\mu\text{g}/\text{plate}$)
Without S9 mixture	2-Nitrofluorene (2-NF)	1

Table S4. Effect of LACC and positive drug samples on CHO-K1 cell viability.

Cell viability (%)			
LACC (mg/mL)	Short-term (3 hr Treatment)		Long-term (18 hr Treatment)
	-S9	+S9	-S9
Dose			
5 mg/mL	32.52 ± 3.53	79.28 ± 2.77	7.69 ± 0.31
2.5 mg/mL	88.01 ± 6.85	99.77 ± 1.95	15.40 ± 1.79
1.25 mg/mL	88.96 ± 6.46	109.18 ± 9.61	65.97 ± 3.34
0.625 mg/mL	90.07 ± 2.81	111.66 ± 6.01	81.23 ± 2.38
0.313 mg/mL	103.44 ± 2.58	117.11 ± 5.14	86.83 ± 1.68
Negative (culture medium)	100.00 ± 12.05	100.00 ± 2.63	100.00 ± 1.02
Mitomycin C	108.58 ± 3.26	-	100.43 ± 3.19
Benzo(a)pyrene	-	81.84 ± 7.06	-

Table S5. *In vivo* mammalian micronucleus test: Mortality.

Groups	Dose	Day						Mortality ^a
		0	1	2	3	4	5	
		Animals found dead						
Negative Control	Sterile water	0	0	0	0	0	0	0/6
Positive Control	Cyclophosphamide 80 mg/kg b.w.	0	0	0	0	0	0	0/6
	0.5 g/kg b.w.	0	0	0	0	0	0	0/6
LACC	1 g/kg b.w.	0	0	0	0	0	0	0/6
	2 g/kg b.w.	0	0	0	0	0	0	0/6

^a: Mortality = Animals found dead/All animals (6 males)

Table S6. *In vivo* mammalian micronucleus test: Mean body weight.

Groups	Dose	Animal Mean Body Weight	
		Male	
		Day1	Day5
Negative Control	Sterile water	32.8 ± 0.7	34.4 ± 1.5
Positive Control	Cyclophosphamide	32.7 ± 0.9	34.2 ± 1.0
LACC	0.5 g/kg b.w.	32.7 ± 0.7	35.0 ± 1.0
	1 g/kg b.w.	33.0 ± 0.7	34.6 ± 0.7
	2 g/kg b.w.	32.5 ± 0.9	34.4 ± 1.2

Table S7. Effect of acute oral dose (14 days) of LACC on rats: Mortality/Moribundity.

Gender	Dose (mg/kg)	Days					2~14	Total Incidence ^a (N/N)
		0 hr	1 hr	1 2 hr	3 hr	4 hr		
		No. of death						
Male	0 ¹	0	0	0	0	0	0	0/6
	1000	0	0	0	0	0	0	0/6
	3000	0	0	0	0	0	0	0/6
	5000	0	0	0	0	0	0	0/6
Female	0 ¹	0	0	0	0	0	0	0/6
	1000	0	0	0	0	0	0	0/6
	3000	0	0	0	0	0	0	0/6
	5000	0	0	0	0	0	0	0/6

¹:Vehicle control: Sterile water for injection (WFI).

^a:Total number of found dead or moribund animals/ Total number of animals.

Table S8. Effect of 90 days repeated oral dose toxicity of LACC on rats: Mortality and ophthalmologic examinations.

Gender	Dose (mg/kg/day)	Mortality (N/N) ¹	Ophthalmologic Examination (N/N)	
			Pre-test	Before Necropsy (Day 91)
Male	0 ^a	0/12	0/12	0/12
	500	0/12	0/12	0/12
	1500	0/12	0/12	0/12
	2500	0/12	0/12	0/12
Female	0 ^a	0/12	0/12	0/12
	500	0/12	0/12	0/12
	1500	0/12	0/12	0/12
	2500	0/12	0/12	0/12

Vehicle control: Sterile water for injection (WFI).

¹ N/N: Number of animals with death or abnormality in ophthalmologic examination /Number of animals examined.

Table S9. Effect of 90 days repeated oral dose toxicity of LACC on rats: Mean body weight in male rats.

Study Day	Mean Body Weights (g, Mean \pm S.D., N = 12)			
	Dose (mg/kg/day)			
	0 ^a	500	1500	2500
Day 1	211.13 \pm 7.39	212.63 \pm 7.61	211.66 \pm 8.54	213.02 \pm 8.21
Day 8	273.83 \pm 10.57	273.38 \pm 12.23	271.59 \pm 12.46	272.51 \pm 12.18
Day 15	324.79 \pm 14.08	325.13 \pm 18.85	321.83 \pm 17.59	321.71 \pm 15.94
Day 22	367.68 \pm 20.46	367.39 \pm 23.77	362.07 \pm 22.89	364.04 \pm 18.67
Day 29	401.89 \pm 26.64	404.19 \pm 27.28	396.44 \pm 27.34	403.53 \pm 23.28
Day 36	430.48 \pm 30.95	432.69 \pm 31.75	421.88 \pm 29.59	433.23 \pm 26.00
Day 43	454.34 \pm 35.02	456.36 \pm 35.63	445.45 \pm 31.45	458.36 \pm 31.32
Day 50	477.44 \pm 38.08	480.98 \pm 38.62	466.86 \pm 34.56	480.23 \pm 34.67
Day 57	496.68 \pm 39.81	500.30 \pm 42.02	480.15 \pm 39.13	499.36 \pm 36.89
Day 64	508.19 \pm 42.90	512.30 \pm 44.23	490.39 \pm 40.89	510.49 \pm 36.58
Day 71	521.29 \pm 42.75	521.66 \pm 46.78	498.63 \pm 43.61	520.15 \pm 36.94
Day 78	533.53 \pm 44.74	535.63 \pm 47.47	507.63 \pm 41.65	530.67 \pm 38.67
Day 85	543.53 \pm 46.40	542.96 \pm 52.42	511.13 \pm 40.03	541.76 \pm 38.27
Day 91	553.65 \pm 47.26	553.04 \pm 55.19	521.79 \pm 40.32	549.46 \pm 37.90

^a Vehicle control: Sterile water for injection (WFI).

Table S10. Effect of 90 days repeated oral dose toxicity of LACC on rats: Mean body weight in female rats.

Study Day	Mean Body Weights (g, Mean \pm S.D., N = 12)			
	Dose (mg/kg/day)			
	0 ^a	500	1500	2500
Day 1	174.74 \pm 11.41	175.91 \pm 6.61	174.44 \pm 5.72	174.13 \pm 5.65
Day 8	199.96 \pm 11.64	198.79 \pm 9.55	197.23 \pm 11.15	203.83 \pm 9.14
Day15	221.04 \pm 12.77	217.14 \pm 11.55	219.19 \pm 14.76	224.93 \pm 11.46
Day22	237.88 \pm 20.44	231.92 \pm 11.61	234.46 \pm 16.15	240.60 \pm 13.39
Day29	251.60 \pm 23.16	244.54 \pm 13.82	248.19 \pm 20.65	253.88 \pm 14.85
Day36	260.71 \pm 24.55	257.28 \pm 17.90	259.96 \pm 25.43	267.28 \pm 19.45
Day43	269.65 \pm 23.88	263.93 \pm 16.33	271.86 \pm 30.44	279.73 \pm 21.10
Day50	277.63 \pm 27.99	269.68 \pm 15.67	280.98 \pm 30.23	288.23 \pm 18.52
Day57	280.53 \pm 30.75	274.25 \pm 18.92	282.81 \pm 32.55	290.57 \pm 17.00
Day64	284.13 \pm 30.44	279.17 \pm 19.22	286.32 \pm 35.03	296.98 \pm 21.40
Day71	288.76 \pm 27.45	282.88 \pm 18.04	291.90 \pm 37.47	301.88 \pm 22.47
Day78	291.58 \pm 29.30	285.20 \pm 17.07	297.03 \pm 35.56	311.18 \pm 21.72
Day85	296.52 \pm 29.72	289.67 \pm 21.27	302.24 \pm 38.05	313.49 \pm 22.30
Day91	297.13 \pm 27.44	292.50 \pm 20.61	301.97 \pm 40.55	315.73 \pm 25.27

^a Vehicle control: Sterile water for injection (WFI).

Table S11. Effect of 90 days repeated oral dose toxicity of LACC on rats: Mean body weight gain in male rats.

Study Week	Mean Body Weights Gains (g, Mean \pm S.D., N = 12)			
	Dose (mg/kg/day)			
	0 ^a	500	1500	2500
Week 1 (Day 8 – Day 1)	62.71 \pm 6.48	60.76 \pm 6.39	59.93 \pm 6.14	59.49 \pm 7.72
Week 2 (Day 15 – Day 8)	50.96 \pm 5.88	51.75 \pm 9.56	50.24 \pm 6.68	49.20 \pm 6.57
Week 3 (Day 22 – Day 15)	42.89 \pm 7.98	42.26 \pm 6.26	40.23 \pm 6.83	42.33 \pm 4.14
Week 4 (Day 29 – Day 22)	34.21 \pm 7.61	36.80 \pm 5.49	34.38 \pm 5.77	39.48 \pm 5.84
Week 5 (Day 36 – Day 29)	28.59 \pm 6.50	28.50 \pm 6.15	25.44 \pm 4.07	29.71 \pm 5.96
Week 6 (Day 43 – Day 36)	23.86 \pm 7.71	23.67 \pm 4.73	23.57 \pm 5.35	25.13 \pm 7.62
Week 7 (Day 50 – Day 43)	23.10 \pm 3.86	24.62 \pm 5.88	21.41 \pm 5.06	21.87 \pm 7.75
Week 8 (Day 57 – Day 50)	19.24 \pm 7.33	19.33 \pm 5.12	13.29 \pm 7.31	19.13 \pm 6.59
Week 9 (Day 64 – Day 57)	11.51 \pm 6.89	12.00 \pm 5.41	10.24 \pm 4.51	11.13 \pm 12.62
Week 10 (Day 71 – Day 64)	13.10 \pm 4.80	9.36 \pm 5.95	8.23 \pm 5.75	9.66 \pm 10.26
Week 11 (Day 78 – Day 71)	12.24 \pm 4.36	13.97 \pm 4.32	9.00 \pm 6.40	10.52 \pm 5.24
Week 12 (Day 85 – Day 78)	9.99 \pm 4.80	7.33 \pm 5.96	3.50 \pm 9.43	11.09 \pm 6.74
Week 13 (Day 91 – Day 85)	10.13 \pm 4.97	10.08 \pm 4.47	10.67 \pm 6.76	7.70 \pm 5.71
Total (Day 91 – Day 1)	342.53 \pm 43.17	340.42 \pm 52.44	310.13 \pm 36.92	336.44 \pm 35.90

^a Vehicle control: Sterile water for injection (WFI).

Table S12. Effect of 90 days repeated oral dose toxicity of LACC on rats: Mean body weight gain in female rats.

Study Week	Mean Body Weights Gains (g, Mean \pm S.D., N = 12)			
	Dose (mg/kg/day)			
	0 ^a	500	1500	2500
Week 1 (Day 8 – Day 1)	25.22 \pm 10.39	22.88 \pm 5.54	22.78 \pm 7.75	29.70 \pm 8.23
Week 2 (Day 15 – Day 8)	21.08 \pm 6.10	18.35 \pm 5.98	21.97 \pm 5.64	21.10 \pm 5.31
Week 3 (Day 22 – Day 15)	16.83 \pm 10.23	14.78 \pm 6.48	15.27 \pm 3.64	15.67 \pm 5.75
Week 4 (Day 29 – Day 22)	13.73 \pm 5.32	12.63 \pm 6.09	13.73 \pm 5.67	13.28 \pm 6.72
Week 5 (Day 36 – Day 29)	9.10 \pm 4.77	12.74 \pm 6.19	11.77 \pm 6.97	13.40 \pm 9.19
Week 6 (Day 43 – Day 36)	8.95 \pm 5.30	6.65 \pm 6.74	11.90 \pm 8.21	12.46 \pm 5.23
Week 7 (Day 50 – Day 43)	7.98 \pm 6.30	5.75 \pm 4.62	9.13 \pm 3.99	8.50 \pm 4.25
Week 8 (Day 57 – Day 50)	2.89 \pm 6.24	4.57 \pm 5.99	1.83 \pm 4.01	2.33 \pm 4.86
Week 9 (Day 64 – Day 57)	3.60 \pm 5.11	4.92 \pm 4.08	3.51 \pm 6.51	6.41 \pm 5.99
Week 10 (Day 71 – Day 64)	4.63 \pm 4.66	3.72 \pm 4.29	5.58 \pm 5.63	4.90 \pm 4.92
Week 11 (Day 78 – Day 71)	2.82 \pm 4.71	2.32 \pm 5.60	5.13 \pm 4.41	9.30 \pm 6.04 *
Week 12 (Day 85 – Day 78)	4.94 \pm 6.57	4.47 \pm 6.96	5.21 \pm 6.05	2.32 \pm 4.81
Week 13 (Day 91 – Day 85)	0.61 \pm 4.76	2.83 \pm 6.64	-0.28 \pm 6.02	2.24 \pm 9.70
Total (Day 91 – Day 1)	122.38 \pm 21.98	116.59 \pm 18.19	127.53 \pm 36.61	141.60 \pm 25.23

^a Vehicle control: Sterile water for injection (WFI).

* $p < 0.05$.

Table S13. Effect of LACC on urine biochemistry.

Gender	Parameters	Dose (mg/kg/day)			
		0 ^a	500	1500	2500
Male	Volume (mL)	19.29 ± 8.95	19.71 ± 6.82	21.92 ± 10.12	18.00 ± 7.99
	Specific Gravity	1.0158 ± 0.0036	1.0158 ± 0.0029	1.0145 ± 0.0027	1.0179 ± 0.0050
	pH	7.04 ± 0.14	7.17 ± 0.25	6.96 ± 0.14	6.71 ± 0.33*
	Urobilinogen (EU/dL)	0.2 ± 0.0	0.2 ± 0.0	0.2 ± 0.0	0.2 ± 0.0
Female	Volume (mL)	17.13 ± 8.06	10.71 ± 3.58*	15.54 ± 7.40	13.54 ± 5.55
	Specific Gravity	1.0150 ± 0.0043	1.0171 ± 0.0040	1.0138 ± 0.0043	1.0150 ± 0.0030
	pH	6.92 ± 0.36	6.83 ± 0.25	6.83 ± 0.33	6.79 ± 0.40
	Urobilinogen (EU/dL)	0.2 ± 0.0	0.2 ± 0.0	0.2 ± 0.0	0.2 ± 0.0

^a Vehicle control: Sterile water for injection (WFI).

* $p < 0.05$.

Table S14. Effect of repeated oral dose (90 days) of LACC on rats: Gross necropsy findings.

Group	Control		Mid-dose		High-dose	
Dose (mg/kg/day)	0 ^a		1500		2500	
Gender	♂	♀	♂	♀	♂	♀
Gross Necropsy Findings	(N/N) ¹					
Liver						
Swelling	1/12	0/12	1/12	0/12	1/12	0/12
Cecum						
Reddish	0/12	0/12	0/12	0/12	1/12	0/12
Thymus						
Atrophy	0/12	0/12	0/12	0/12	1/12	0/12
Epididymides						
Edema, bilateral	0/12	-	0/12	-	1/12	-
Kidneys						
White macula, left kidney	0/12	0/12	0/12	0/12	0/12	1/12

^a Vehicle control: Sterile water for injection (WFI).

¹ N/N: Number of animals with observable abnormality /Number of animals examined.

These gross findings were considered as spontaneous lesions or non-test article related changes after histopathologic evaluation.

Table S15. Effect of repeated oral dose (90 days) of LACC on rats: Histopathological findings.

Dose (mg/kg/day)		0		2500		
Gender		♂	♀	♂	♀	
Histopathological Findings	severity ²	Incidence (N/N) ¹				p value
Adrenals						
Atrophy, cortex, locally extension.	Minimal	0/12	2/12	0/12	0/12	> 0.05*
Vacuolar degeneration cortex, locally extension.	Minimal	1/12	0/12	2/12	0/12	> 0.05*
Atrophy, medulla, focal.	Minimal	0/12	0/12	0/12	1/12	> 0.05*
Pancreas						
Acinar cell metaplasia, foci.	Mild	1/12	0/12	0/12	0/12	> 0.05*
Harderian glands						
FRCC, interstitial, focal.	Minimal	2/12	2/12	2/12	2/12	> 0.05*
FRCC, interstitial, foci.	Minimal	0/12	0/12	1/12	1/12	> 0.05*
Fibrosis, interstitial, foci.	Minimal	0/12	0/12	0/12	1/12	> 0.05*
Heart						
Myocarditis, focal, R't ventricle.	Minimal	0/12	1/12	0/12	0/12	> 0.05*
Myocarditis, focal, L't ventricle.	Minimal	0/12	0/12	1/12	0/12	> 0.05*
Focal necrosis, myocardial, focal, R't ventricle.	Minimal	1/12	0/12	1/12	0/12	> 0.05*
Focal necrosis, myocardial, focal, L't ventricle.	Minimal	1/12	0/12	0/12	0/12	> 0.05*
Kidney						
Nephrosclerosis, cortex, foci, L't kidney.	Minimal	1/12	1/12	2/12	0/12	> 0.05*
Nephrosclerosis, medulla, foci, L't kidney.	Minimal	1/12	0/12	0/12	0/12	> 0.05*
Nephropathy, interstitial, cortex, foci, L't kidney.	Minimal	1/12	0/12	1/12	0/12	> 0.05*
Nephropathy, interstitial, cortex, foci, Bilateral kidney.	Minimal	0/12	0/12	2/12	0/12	> 0.05*
Nephropathy, interstitial, cortex, foci, R't kidney.	Minimal	0/12	1/12	0/12	0/12	> 0.05*
Mineralization, tubular lumen, medulla, foci, R't kidney.	Minimal	0/12	0/12	0/12	1/12	> 0.05*
Mineralization, tubular lumen, medulla, foci, Bilateral kidney.	Minimal	0/12	0/12	0/12	2/12	> 0.05*
Neoplasma, nephroblastoma, cortex and medulla, locally extension, L't kidney.	Mild	0/12	0/12	0/12	1/12	> 0.05*
Liver						
FRCC, central lobular, foci.	Minimal	1/12	1/12	0/12	0/12	> 0.05*
FRCC, central lobular, focal.	Minimal	2/12	2/12	0/12	2/12	> 0.05*
Thromboembolus, central vein.	Minimal	1/12	0/12	0/12	0/12	> 0.05*
Lung						
Epithelial necrosis, bronchial, focal.	Minimal	0/12	1/12	0/12	0/12	> 0.05*
Epididymides						
FRCC, interstitial, focal.	Minimal	1/12	- ^b	2/12	- ^b	> 0.05*
FRCC, interstitial, foci.	Minimal	1/12	- ^b	0/12	- ^b	> 0.05*
Seminal vessels						
FRCC, intratubular, focal.	Minimal	0/12	- ^b	2/12	- ^b	> 0.05*
Mammary Gland						
Clear cell with abundant hyaline droplets, lobular, focal.	Minimal	- ^b	1/12	- ^b	0/12	> 0.05*
Prostate						
FRCC, stromal, focal.	Minimal	3/12	- ^b	5/12	- ^b	> 0.05*
FRCC, stromal, foci.	Minimal	0/12	- ^b	1/12	- ^b	> 0.05*
Pituitary						
Cyst, adenohypophysis, focal.	Minimal	1/12	0/12	1/12	0/12	> 0.05*

^a Vehicle control: Sterile water for injection (WFI).

^b -: No data available.

¹ N/N: Animal numbers of histopathologic findings / Animal numbers of histopathologic examinations.

² The severity grading scheme: minimal (< 10 %), mild (10-39 %), moderate (40-79 %), marked (80-100 %).

³ Abbreviation: L't = Left; R't = Right; *= With Fisher exact test of two-tailed examination.

Table S16. Effect of LACC maternal clinical observation.

Clinical Signs	Group	Dose Level	Total Incidence
		mg/kg/day	(n/n) ^a
Hair loss (Slight to moderate)	Vehicle Control	0	2/21
	Low-dose	500	0/20
	Mid-dose	1500	0/20
	High-dose	2500	1/21

^a: n/n: Total of abnormal animals observed/Total of pregnant verified animal number.

Table S17. Effect of LACC on maternal evaluation.

	Dose Level (mg/kg/day)				Normal reference range
	0	500	1500	2500	
	Vehicle control	Low-dose	Mid-dose	High-dose	
Impregnation verified animal number	25	23	22	22	617 ^b
Pregnant verified animal number	21	20	20	21	589 ^b
Fertility Index (%)	84	86.96	90.91	95.45	87.5 - 100.0 ^b
Uterus Weight (g)	86.772 ± 13.061	79.885 ± 21.100	85.678 ± 8.140	85.558 ± 10.799	73.24 - 117.80 ^b
Implantation Number	15.7 ± 1.9	14.4 ± 3.3	15.2 ± 1.7	14.5 ± 1.7	13.5 - 16.0 ^b
Corpora lutea Number	15.6 ± 1.7	15.1 ± 2.0	15.5 ± 1.4	15.3 ± 1.7	14.6 - 18.3 ^b
Litter size	15.0 ± 2.4	13.6 ± 3.8	14.6 ± 1.7	14.1 ± 1.7	8.51 - 17.05 ^d
Live fetus Number	15.0 ± 2.4	13.6 ± 3.8	14.6 ± 1.7	14.1 ± 1.7	8.51 - 17.05 ^d
Fetus Male Number	7.8 ± 2.2	6.7 ± 2.5	8.3 ± 1.6	6.9 ± 2.1	3.10 - 9.00 ^d
Fetus Female Number	7.1 ± 2.7	6.9 ± 3.1	6.3 ± 1.7	7.2 ± 2.2	3.84 - 10.16 ^d
Death fetus Number	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0 ^d
Resorptions Number	0.4 ± 0.7	0.8 ± 1.2	0.6 ± 0.9	0.3 ± 0.6	0.2 - 1.2 ^b
Sex Ratio (M/F)	1.36 ± 0.93	1.19 ± 0.76	1.53 ± 1.13	1.16 ± 0.78	0.74 - 1.34 ^b
Pre-implantation loss (%)	-0.30 ± 4.84	6.27 ± 16.70	1.86 ± 8.08	5.13 ± 6.71*	4.2 - 17.8 ^a
Post-implantation loss (%)	4.77 ± 8.38	7.36 ± 12.74	4.04 ± 6.63	2.88 ± 4.95	2.2 - 10.8 ^a

*: Statistically significant difference with vehicle control group. $p < 0.05$.

^a: Historical Control Data Rat CD® IGS (crI:CD[SD]), 1996-2004. Charles River Laboratories Preclinical Service, Montreal.

^b: Historical Control Data Rat CD® IGS (crI:CD[SD]), 2003-2005. Charles River Laboratories Preclinical Service, Pennsylvania.

^d: Historical Control Data Rat CD® IGS, Level Biotechnology Inc.